Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Cummin, Thomas"" wg kryterium: Autor


Wyświetlanie 1-18 z 18
Tytuł :
Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality
Autorzy :
Cucco, Francesco
Clipson, Alexandra
Kennedy, Hannah
Sneath Thompson, Joe
Wang, Ming
Barrans, Sharon
van Hoppe, Moniek
Ochoa Ruiz, Eguzkine
Caddy, Josh
Hamid, Debbie
Cummin, Thomas
Burton, Cathy
Davies, Andrew J
Johnson, Peter
Du, Ming-QingAff1, Aff5
Pokaż więcej
Źródło :
Laboratory Investigation: Advancing the understanding of human and experimental disease. 98(8):1084-1092
Czasopismo naukowe
Tytuł :
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Autorzy :
Davies, Andrew
Cummin, Thomas E
Barrans, Sharon
Maishman, Tom
Mamot, Christoph
Novak, Urban
Caddy, Josh
Stanton, Louise
Kazmi-Stokes, Shamim
McMillan, Andrew
Fields, Paul
Pocock, Christopher
Collins, Graham P
Stephens, Richard
Cucco, Francesco
Clipson, Alexandra
Sha, Chulin
Tooze, Reuben
Care, Matthew A
Griffiths, Gareth
Du, Ming-Qing
Westhead, David R
Burton, Catherine
Johnson, Peter WM
Pokaż więcej
Temat :
610 Medicine & health
Article
Źródło :
Davies, Andrew; Cummin, Thomas E; Barrans, Sharon; Maishman, Tom; Mamot, Christoph; Novak, Urban; Caddy, Josh; Stanton, Louise; Kazmi-Stokes, Shamim; McMillan, Andrew; Fields, Paul; Pocock, Christopher; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Clipson, Alexandra; Sha, Chulin; Tooze, Reuben; Care, Matthew A; Griffiths, Gareth; ... (2019). Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. The lancet oncology, 20(5), pp. 649-662. Elsevier 10.1016/S1470-2045(18)30935-5
Opis pliku :
application/pdf
Tytuł :
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Autorzy :
Davies A; Cancer Research UK Centre, University of Southampton, Southampton, UK; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
Cummin TE; Cancer Research UK Centre, University of Southampton, Southampton, UK; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
Barrans S; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, UK.
Maishman T; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
Mamot C; Medical Oncology, Cantonal Hospital Aarau, Switzerland.
Novak U; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Caddy J; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
Stanton L; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
Kazmi-Stokes S; Centre for Drug Development, Cancer Research UK, London, UK.
McMillan A; Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Fields P; Department of Haematology, Guy's and St Thomas' Hospitals NHS Trust, Kings Health Partners, London, UK.
Pocock C; Department of Haematology, East Kent Hospitals University Foundation Trust, Canterbury, UK.
Collins GP; Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK.
Stephens R; National Cancer Research Institute Consumer Forum, London, UK.
Cucco F; Department of Pathology, University of Cambridge, Cambridge, UK.
Clipson A; Department of Pathology, University of Cambridge, Cambridge, UK.
Sha C; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Tooze R; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, UK; Section of Experimental Haematology, University of Leeds, Leeds, UK.
Care MA; Section of Experimental Haematology, University of Leeds, Leeds, UK.
Griffiths G; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
Du MQ; Department of Pathology, University of Cambridge, Cambridge, UK.
Westhead DR; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Burton C; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, UK.
Johnson PWM; Cancer Research UK Centre, University of Southampton, Southampton, UK. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2019 May; Vol. 20 (5), pp. 649-662. Date of Electronic Publication: 2019 Apr 01.
Typ publikacji :
Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Profiling*
Transcriptome*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Biomarkers, Tumor/*genetics
Bortezomib/*administration & dosage
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Proteasome Inhibitors/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Disease Progression ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/immunology ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Progression-Free Survival ; Proteasome Inhibitors/adverse effects ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Switzerland ; Time Factors ; United Kingdom ; Vincristine/administration & dosage ; Vincristine/adverse effects ; Young Adult
Czasopismo naukowe
    Wyświetlanie 1-18 z 18

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies